<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIM: Incretin enhancers are a new class of <z:chebi fb="0" ids="35526">antidiabetic</z:chebi> drugs with promising therapeutic potential for type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>Therapeutic intervention in <z:e sem="disease" ids="C0362046" disease_type="Disease or Syndrome" abbrv="">prediabetes</z:e> is an attractive strategy for preventing or delaying <z:mp ids='MP_0002055'>diabetes</z:mp> <z:hpo ids='HP_0003674'>onset</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>The aim of the present study was to investigate the therapeutic effects of incretin enhancement on incipient <z:hpo ids='HP_0000833'>impaired glucose tolerance</z:hpo> (iIGT) and manifest IGT (mIGT) using the dipeptidyl peptidase IV (DPP-4) inhibitor P32/98- and fatty <z:chebi fb="3" ids="16646">Zucker</z:chebi> rat (ZR, fa/fa) as a model </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: ZRs were classified into groups with iIGT and mIGT (n = 10 per group) </plain></SENT>
<SENT sid="4" pm="."><plain>P32/98 (21.61 mg/kg body weight) was administered orally to ZR with iIGT and mIGT once daily for 6 and 3 weeks respectively </plain></SENT>
<SENT sid="5" pm="."><plain>Assessments included body weight, morning blood <z:chebi fb="105" ids="17234">glucose</z:chebi> and insulin, oral <z:chebi fb="105" ids="17234">glucose</z:chebi> tolerance test (oGTT; 2 g <z:chebi fb="105" ids="17234">glucose</z:chebi>/kg), plasma parameters and blood <z:chebi fb="105" ids="17234">glucose</z:chebi> day-night profile (<z:chebi fb="0" ids="53018">DNP</z:chebi>) </plain></SENT>
<SENT sid="6" pm="."><plain>In addition, <z:chebi fb="105" ids="17234">glucose</z:chebi> responsiveness of isolated islets and islet <z:mp ids='MP_0000002'>morphology</z:mp> were analysed </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: P32/98 decreased non-fasting morning blood <z:chebi fb="105" ids="17234">glucose</z:chebi> more effectively in ZR with iIGT than in ZR with mIGT </plain></SENT>
<SENT sid="8" pm="."><plain>Compared with study entry, P32/98 improved <z:chebi fb="0" ids="53018">DNP</z:chebi> of blood <z:chebi fb="105" ids="17234">glucose</z:chebi> in ZR with mIGT and nearly normalized <z:chebi fb="0" ids="53018">DNP</z:chebi> in ZR with iIGT </plain></SENT>
<SENT sid="9" pm="."><plain>An <z:hpo ids='HP_0011009'>acute</z:hpo> bolus of inhibitor reduced <z:chebi fb="105" ids="17234">glucose</z:chebi> load during oGTT in rats chronically treated with placebo or P32/98 </plain></SENT>
<SENT sid="10" pm="."><plain>In contrast to placebo-treated rats, rats receiving long-term treatment with P32/98 required less insulin during oGTT </plain></SENT>
<SENT sid="11" pm="."><plain>This effect was larger in rats with iIGT vs. rats with mIGT </plain></SENT>
<SENT sid="12" pm="."><plain>In isolated pancreatic islets of ZR with mIGT, treatment with P32/98 decreased pancreatic insulin content and increased <z:chebi fb="105" ids="17234">glucose</z:chebi> responsiveness, while the beta-cell volume density was unaffected </plain></SENT>
<SENT sid="13" pm="."><plain>P32/98 significantly reduced <z:chebi fb="4" ids="17855">triglycerides</z:chebi> and non-esterified fatty acids </plain></SENT>
<SENT sid="14" pm="."><plain>Intestinal growth was comparable between inhibitor- and placebo-treated fatty rats </plain></SENT>
<SENT sid="15" pm="."><plain>CONCLUSIONS: Enhancement of incretin with the DPP-4 inhibitor P32/98 has therapeutic effects in <z:e sem="disease" ids="C0020459" disease_type="Disease or Syndrome" abbrv="">hyperinsulinaemia</z:e>, <z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">hyperglycaemia</z:e> and IGT in ZR with iIGT and mIGT </plain></SENT>
<SENT sid="16" pm="."><plain>Apparently, administration of P32/98 in ZR with iIGT results in more efficient beta-cell function, which is associated with less need for insulin to cope with deterioration of <z:chebi fb="105" ids="17234">glucose</z:chebi> tolerance </plain></SENT>
<SENT sid="17" pm="."><plain>Importantly, P32/98 has a strong effect on <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidaemia</z:e> in mIGT </plain></SENT>
<SENT sid="18" pm="."><plain>P32/98 has no side effect on intestinal growth </plain></SENT>
<SENT sid="19" pm="."><plain>Daily intake of P32/98 is a promising strategy for treatment of <z:hpo ids='HP_0000833'>glucose intolerance</z:hpo> and has the potential to prevent type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
</text></document>